Correlation Between FrontView REIT, and BioCryst Pharmaceuticals

Can any of the company-specific risk be diversified away by investing in both FrontView REIT, and BioCryst Pharmaceuticals at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining FrontView REIT, and BioCryst Pharmaceuticals into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between FrontView REIT, and BioCryst Pharmaceuticals, you can compare the effects of market volatilities on FrontView REIT, and BioCryst Pharmaceuticals and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in FrontView REIT, with a short position of BioCryst Pharmaceuticals. Check out your portfolio center. Please also check ongoing floating volatility patterns of FrontView REIT, and BioCryst Pharmaceuticals.

Diversification Opportunities for FrontView REIT, and BioCryst Pharmaceuticals

0.29

Correlation Coefficient

FrontView REIT,  BioCryst Pharmaceuticals

Modest diversification

The 3 months correlation between FrontView and BioCryst is 0.29. Overlapping area represents the amount of risk that can be diversified away by holding FrontView REIT, and BioCryst Pharmaceuticals in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on BioCryst Pharmaceuticals and FrontView REIT, is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on FrontView REIT, are associated (or correlated) with BioCryst Pharmaceuticals. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of BioCryst Pharmaceuticals has no effect on the direction of FrontView REIT, i.e., FrontView REIT, and BioCryst Pharmaceuticals go up and down completely randomly.

Pair Corralation between FrontView REIT, and BioCryst Pharmaceuticals

Considering the 90-day investment horizon FrontView REIT, is expected to under-perform the BioCryst Pharmaceuticals. But the stock apears to be less risky and, when comparing its historical volatility, FrontView REIT, is 1.31 times less risky than BioCryst Pharmaceuticals. The stock trades about -0.21 of its potential returns per unit of risk. The BioCryst Pharmaceuticals is currently generating about 0.04 of returns per unit of risk over similar time horizon. If you would invest  753.00  in BioCryst Pharmaceuticals on December 29, 2024 and sell it today you would earn a total of  33.00  from holding BioCryst Pharmaceuticals or generate 4.38% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Very Weak
Accuracy	100.0%
Values	Daily Returns

FrontView REIT,  vs.  BioCryst Pharmaceuticals

FrontView REIT,

Risk-Adjusted Performance

Very Weak

Over the last 90 days FrontView REIT, has generated negative risk-adjusted returns adding no value to investors with long positions. Even with conflicting performance in the last few months, the Stock's basic indicators remain relatively invariable which may send shares a bit higher in April 2025. The latest agitation may also be a sign of long-running up-swing for the enterprise retail investors.

BioCryst Pharmaceuticals

Risk-Adjusted Performance

Weak

Compared to the overall equity markets, risk-adjusted returns on investments in BioCryst Pharmaceuticals are ranked lower than 3 (%) of all global equities and portfolios over the last 90 days. In spite of fairly weak basic indicators, BioCryst Pharmaceuticals may actually be approaching a critical reversion point that can send shares even higher in April 2025.

Pair Trading with FrontView REIT, and BioCryst Pharmaceuticals

The main advantage of trading using opposite FrontView REIT, and BioCryst Pharmaceuticals positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if FrontView REIT, position performs unexpectedly, BioCryst Pharmaceuticals can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in BioCryst Pharmaceuticals will offset losses from the drop in BioCryst Pharmaceuticals' long position.

The idea behind FrontView REIT, and BioCryst Pharmaceuticals pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Price Exposure Probability module to analyze equity upside and downside potential for a given time horizon across multiple markets.